Pancreatic Cancer Clinical Trials in Philadelphia

Showing 121-125 of 125 trials

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911

Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine

Metastatic Pancreatic Cancer

Eli Lilly and Company61 participantsStarted May 2006

Jonesboro, Arkansas, United States • San Francisco, California, United States • Stamford, Connecticut, United States +13 more locations

TERMINATEDPhase 3< 1 mile

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

Pancreatic CancerPerioperative/Postoperative Complications

Mayo ClinicStarted Mar 2001

Birmingham, Alabama, United States • Tampa, Florida, United States • Chicago, Illinois, United States +15 more locations

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Pancreatic Cancer Trials in Other Cities

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers

Other Conditions in Philadelphia